SCHEMBL1110656

SCHEMBL1110656

FC(F)(F)c1ccc(N2CCC3CCCCC3C2)c(NC(=S)c2ccncc2)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRPK1 Q96SB4 4/20 0.55
KDR P35968 1/20 0.55
SRPK2 P78362 1/20 0.55
SRPK3 Q9UPE1 1/20 0.55
CDK4 P11802 1/20 0.52
CDK9 P50750 1/20 0.52
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 4/20 0.40
NPSR1 Q6W5P4 4/20 0.40
ALOX12 P18054 1/20 0.40
HSD17B10 Q99714 2/20 0.38
PHGDH O43175 1/20 0.38
TSHR P16473 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KCNH2 Q12809 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110657 1.00 SRPK1 (0.55) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL1110655 1.00 SRPK1 (0.55) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL20117644 0.90 LMNA (0.42) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL15849107 0.90 MAPT (0.44) SRPK1KDRSRPK2SRPK3LMNA
SCHEMBL1110553 0.89 SRPK1 (0.70) SRPK1KDRSRPK2SRPK3LMNA
SCHEMBL1110551 0.89 SRPK1 (0.70) SRPK1KDRSRPK2SRPK3LMNA
SCHEMBL1110556 0.89 SRPK1 (0.70) SRPK1KDRSRPK2SRPK3LMNA
SCHEMBL15277931 0.88 SRPK1 (0.44) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL15277956 0.88 KDR (0.44) SRPK1KDRSRPK2SRPK3CDK4
SCHEMBL21322827 0.86 MEN1 (0.45) SRPK1KDRSRPK2SRPK3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765941-B2 Aniline derivative having anti-RNA viral activity KINO PHARMA, INC. (JP) 2014-07-01 US disclosed
US-20110059950-A1 ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY KINOPHARMA, INC. (JP) 2011-03-10 US disclosed
EP-2279750-A1 ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY KinoPharma, Inc. (JP) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059950-A1 ANILINE DERIVATIVE HAVING ANTI-RNA VIRAL ACTIVITY RNASEH1, SARS1, ADAR SRPK1 421/4885KDR 3943/4885SRPK2 507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.